Pacific Biosciences of California now sits against a Fair Value estimate of US$2.40 per share, up from US$2.16, giving investors an updated anchor for how analysts see the stock’s potential worth. That change comes alongside Street research that includes a Neutral rating and a US$1.35 price target from UBS, which points to a more cautious stance even as valuation models adjust. Read on to see how these shifting reference points fit into the broader analyst narrative and what to watch as the story evolves.
Stay updated as the Fair Value for Pacific Biosciences of California shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pacific Biosciences of California.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
The refreshed Fair Value estimate of US$2.40 per share for Pacific Biosciences of California offers investors a higher reference point for what some models view as justified valuation, compared with the prior US$2.16 figure.
-
UBS includes PacBio within a broader group of 25 life science and diagnostics tools companies that it views as exposed to end markets that have historically grown faster than overall global economic activity, which some investors may see as a supportive backdrop for long term demand.
🐻 Bearish Takeaways
-
UBS assumed coverage of Pacific Biosciences of California with a Neutral rating and a US$1.35 price target. This sits below the current Fair Value estimate and points to a more reserved stance on near term upside.
-
The Neutral rating from UBS signals that, in the firm’s view, the balance between PacBio’s execution risks and growth prospects does not yet justify a more positive recommendation at current levels.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 3 risks for Pacific Biosciences of California. See which could impact your investment.
How This Changes the Fair Value For Pacific Biosciences of California
-
Fair value has moved from US$2.16 to US$2.40 per share.
-
Revenue growth is now set at about 12.29% compared with the prior 12.64%.
-
Net profit margin is now roughly 16.01% versus about 16.53% previously.
-
Future P/E has shifted from about 27.2x to roughly 29.9x.
-
The discount rate is now about 9.91% compared with the earlier 11.83%.
Never Miss an Update: Follow The Narrative
Narratives connect Pacific Biosciences of California’s business story to a structured set of assumptions on revenue, margins, risks, and fair value. They refresh automatically when analysts update their views or new company information is released.